Canada markets open in 6 hours 53 minutes

Small Pharma Inc. (DMT.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1550+0.0050 (+3.33%)
At close: 10:43AM EDT
Full screen
Previous Close0.1500
Open0.1500
Bid0.1500 x N/A
Ask0.1650 x N/A
Day's Range0.1500 - 0.1550
52 Week Range0.0850 - 0.7000
Volume1,551
Avg. Volume126,840
Market Cap49.987M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0710
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder

    Dosing for primary endpoint now completeLONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has completed enrollment in the Phase IIa clinical trial of its intravenous (“IV”) formulation of N, N-dimethyltryptamine (“DMT”) candidate, SPL026, with psychotherapy for the treatment of Major Depressiv

  • GlobeNewswire

    Small Pharma Enters Into Automatic Share Purchase Plan

    LONDON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announced that it has entered into an automatic share purchase plan (the “ASPP”) with Eight Capital (the “Broker”) in order to facilitate repurchases of the Company's common shares (the “Shares”) under its previously announced normal course issuer bid (the “NCIB

  • GlobeNewswire

    Small Pharma to Participate in Upcoming September Investor Conferences

    LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in upcoming investor conferences this September. Details of the sessions are as follows: H.C. Wainwright 24th Annual Global Investment